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Purpose. Desmoid-type fibromatosis (DTF) is a rare, nonmetastasising soft tissue tumour. Symptoms, unpredictable growth, lack
of definitive treatments, and the chronic character of the disease can significantly impact health-related quality of life (HRQoL).
We aimed at identifying the most important HRQoL issues according to DTF patients in two countries, in order to devise a
specific HRQoL questionnaire for this patient group. Methods. DTF patients and healthcare providers (HCPs) from the
Netherlands and the United Kingdom individually ranked 124 issues regarding diagnosis, treatment, follow-up, recurrence, living
with DTF, healthcare, and supportive care experiences, according to their relevance. Descriptive statistics were used to calculate
priority scores. Results. 'e most highly ranked issues by patients (n� 29) were issues concerning “tumour growth,” “feeling that
there is something in the body that does not belong there,” and “fear of tumour growth into adjacent tissues or organs” with mean
(M) scores of 3.0, 2.9, and 2.8, respectively (Likert scale 1–4). British patients scored higher on most issues compared to Dutch
patients (M 2.2 vs. M 1.5). HCPs (n� 31) gave higher scores on most issues compared to patients (M 2.3 vs. M 1.8). Conclusion.
'is study identified the most relevant issues for DTF patients, which should be included in a DTF-specific HRQoL questionnaire.
Additionally, we identified differences in priority scores between British and Dutch participating patients. Field testing in a large,
international cohort is needed to confirm these findings and to devise a comprehensive and specific HRQoL questionnaire for
DTF patients.
1. Introduction
Sporadic desmoid-type fibromatosis (DTF) is a rare, bor-
derline tumour of the soft tissues [1–3]. Most patients are
females, aged between 20 and 40 years at primary diagnosis [3].
Sporadic DTF arises in musculoaponeurotic structures with
the most common sites being the abdominal wall and the
extremities [4]. Symptoms vary, depending on tumour site,
size, and infiltration of adjacent structures, resulting in pain
and/or functional impairment. DTF does not metastasize,
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rarely has fatal outcomes, often displays long periods of
spontaneous stabilisation, and can undergo spontaneous re-
gression [5]. Surgical resection, radiotherapy, and non-
cytotoxic and cytotoxic systemic therapies may be considered
in patients with symptomatic disease, but unfortunately, these
“traditional” treatment options do not guarantee tumour re-
duction and/or clinical response [6]. Local recurrence after
surgery remains high [7, 8], leading to a reduction in surgical
treatments for DTF over recent decades [3, 4]. Additionally,
“active” forms of treatment can be debilitating, causing greater
morbidity than the tumour itself. For these reasons, active
surveillance is now recommended as a first-line management
formost patients withDTF [6, 9].'erefore, DTF has obtained
a “chronic” status and its impact on patients should be
evaluated accordingly.
Health-related quality of life (HRQoL) provides infor-
mation beyond traditional measures of efficacy in oncology
such as overall survival and is increasingly used as an
endpoint in clinical trials [10, 11]. We previously performed
a systematic literature review to evaluate which HRQoL
measures were used in research to assess HRQoL in DTF
[12]. Generic HRQoLmeasures (e.g., the cancer-specific core
questionnaire from EuropeanOrganisation for Research and
Treatment of Cancer; the EORTC Quality of Life Core
Questionnaire (EORTC QLQ-C30)) may not consider dis-
ease-specific issues in DTF patients. Site-specific tools (e.g.,
Toronto Extremity Salvage Score) may not be relevant to
certain groups (e.g., those with abdominal wall or head and
neck tumours).
At present, there is no validated DTF-specific HRQoL
tool, and this was illustrated by a systematic literature review
published by our group [12, 13]. In order to gain greater
insight into the issues that patients with DTF experience in
their daily lives, and to evaluate their experiences of
healthcare including the supportive care system, we previ-
ously organised focus groups and semistructured interviews,
in the United Kingdom (UK) and in the Netherlands (NL)
[12, 13]. 'ese studies identified issues covering various
domains including the diagnostic pathway, the treatment
pathway, daily limitations (e.g., physical and psychological
symptoms), and experiences with the current healthcare
system.
'e main goal of this study was to determine the relative
importance of each issue and receiving feedback on the
appropriateness of content and breadth of coverage. In the
present study, we used the previously identified issues to (1)
identify the most relevant issues to patients with DTF in two
healthcare settings (UK and NL) and to (2) identify dif-
ferences in scores between both countries.
2. Materials and Methods
2.1. Identification of Issues. 'e EORTC Quality of Life
Group methodology for developing a questionnaire was
used for the selection of relevant issues based on previous
focus groups and patients interviews [14]. Issues that had
previously been identified to be of concern to DTF patients
were listed per country (UK and NL). A total of 188 issues
were identified in the UK group and 110 issues were
identified in the Dutch group. Next, issues were grouped
into categories and duplicate issues covering the same topics
were removed. A total of 124 issues were converted into a
provisional list of issues. All issues were reviewed by two
authors (MT and OH). All issues were translated by native
English and Dutch speakers.
2.2. Patient Selection. Patients with DTF were approached
for participation by their treating physician. Inclusion cri-
teria were histologically proven DTF, age ≥18 years, Dutch
or English language skills, and a “recent” visit (<2 years) to
the hospital. Exclusion criteria were participation in one of
the previous focus groups or patient interviews and patients
with a diagnosis of cancer or familial adenomatous polyposis
(FAP). Patients received an information letter which
explained study objectives. Baseline characteristics and
details about the individual disease trajectory of participants
were obtained. Patients were only invited to participate once
and did not have to provide a reason if they declined. No
reminders were sent. All data from patients was collected
and processed anonymously.
2.3. Selection of Healthcare Providers. To examine whether
HCPs with expertise and experience in sarcomas and DTF
have the same perspectives as patients with DTF about key
HRQoL issues, an e-survey of the same 124 issues was
created using LimeSurvey Servicebedrijf© software. 'e
issue list was available in two languages (Dutch and English),
and issues were presented in a random order. In the
Netherlands, HCPs from the multidisciplinary team (e.g.,
surgeons, oncologists, radiologists, radiotherapists, sarcoma
clinical nurse specialists, and physiotherapists) were iden-
tified using the website Orphanet, which provides infor-
mation on centres of expertise dedicated to the medical
management for rare diseases (https://www.orpha.net/
consor/cgi-bin/Clinics_Search.php?lng�EN). In the UK,
HCPs of the aforementioned disciplines were identified
using the sarcoma network group of the Royal Marsden
Hospital, London, UK. Every HCP received an invitation
email with a token and link to the e-survey. A reminder was
sent after one week if the HCP had not responded.
2.4. Sociodemographic and Clinical Characteristics. Age at
the time of diagnosis was either stated by the patient or
calculated using the date of birth and date of the first pa-
thology report. Age at the time of questionnaire completion
was either stated by the patient or calculated using the date of
informed consent and the date of birth. Education levels
were categorized into “high” (PhD, university, and higher
education postgraduate/undergraduate degree), “interme-
diate” (professional qualification, vocational work, work-
related qualification, general secondary education, and
further/intermediate education), and “low” (primary edu-
cation (with a higher, but not completed education) and
secondary education). Continuous variables were presented
as a mean with a standard deviation (SD) or as a median with
2 Sarcoma
an interquartile range (IQR). Categorical variables were
presented as number (n) using frequencies and percentages.
2.5. Presentation of Issues to Patients and Healthcare
Providers. A total of 124 issues were presented to patients
and healthcare providers (HCPs) in a random order
(Supplemental Table 1). Patients and HCPs scored 124 issues
by relevance on a Likert scale from 1 to 4 ((1) not at all, (2) a
little, (3) quite a bit, and (4) very much) and ranked the top
ten most important issues. 'e frequency that each issue
appeared in the top ten most important issues was converted
into the mean priority score (M-score) per issue. 'e fre-
quency of the top ten priority score of each issue was cal-
culated and ranked in overall priority score. Where
questions were left blank by the participant, they were coded
as a “missing value” and not incorporated in the total score.
Space for general remarks was available at the end of the
questionnaire.
2.6. EORTC QLQ-C30 Questionnaire. In addition to the
issue list, patients were asked to fill out the 30-item EORTC
QLQ-C30 questionnaire (version 3) to assess HRQoL [15].
Norm data were obtained from the EORTC, which recently
collected data from the general population in Europe and
North America [16]. Only data from the general population
in the Netherlands and the UK were used for the current
study. 'e EORTC QLQ-C30 questionnaire contains five
functional scales (physical, role, cognitive, emotional, and
social functioning), a global health status scale, three
symptom scales (fatigue, nausea and vomiting, and pain),
and six single items (appetite loss, diarrhoea, dyspnoea,
constipation, insomnia, and financial difficulties). 'e
questionnaire has a 1-week time frame and uses a four-point
response format (“not at all,” “a little,” “quite a bit,” and
“very much”), with the exception of the global health status
scale, which has a seven-point response format. 'e scores
were calculated using linear transformation to a score be-
tween 0 and 100. For the functional scales and the global
health status, a high score represents a high (healthy) level of
functioning. A high score for the symptom scales represents
a high level of symptoms (greater symptom burden) [17].
'e EORTC QLQ-C30 summary score was calculated using
the mean scores of the function scales and the reversed mean
scores of the symptom scales and single items (financial
impact and global health status excluded) and is summarized
as the mean of the combined 13 QLQ-C30 scale scores. A
higher summary score represented a better outcome [18, 19].
'e summary score was only calculated when all of the
required 13 scale and item scores were available. Data
analysis and handling of missing items were done according
to the scoring manual of the EORTC [17].
2.7. StatisticalAnalysis. Patients were matched, using a 1 :10
nearest-neighbour match method, with the general pop-
ulation based on nationality, age, and sex using RStudio
(RStudio, version 1.0.153, Boston, MA, package MatchIt).
Patients with missing values (lacking information regarding
age or sex) were excluded from the analysis. Differences in
priority scores (Dutch versus British participating patients
and HCPs versus participating patients) and differences in
scores of the EORTC QLQ-C30 scales between groups
(Dutch versus British participating patients and Dutch and
British participating patients versus the Dutch and British
general population) were tested for their significance using
the Mann–Whitney U test. SPSS Statistics (version 24) was
used for the Mann–Whitney U tests (IBM, Armonk, New
York, USA). Two-sided p< 0.05 was considered statistically
significant.
3. Results
3.1.PatientCohort. Forty-one patients from the ErasmusMC,
Rotterdam, the Netherlands, and 32 patients from the Royal
Marsden Hospital, London, UK, were approached during July
and August 2018. Out of 73 patients, 29 patients (total re-
sponse rate of 39.7%) gave written informed consent (Fig-
ure 1). 'e cohort comprised of 10 males and 19 females with
DTF most commonly localized in the extremities, flank, and
chest wall (n� 15, 52%). Nine participants had received active
treatment at the time of the questionnaire. 'e median, self-
reported age at diagnosis was 38 years (IQR 30–48) (Table 1).
Sociodemographic characteristics are summarized in Sup-
plemental Table 1. All participants completed the issue list, and
sixteen participants ranked their top 10 most relevant issues.
3.2. Ranking of Priority of the Issues. Ranking of HRQoL
issues revealed that 13 out of 124 issues (10.5%) were chosen
to be the most relevant (prevalence ratio of >30%) (Table 2).
Patients considered the following issues as relevant and
missing on the current issue list: “problems with healthcare
insurances,” “coverage of costs related to the disease such as
traveling costs,” “lack of adequate online information,” “lack
of knowledge about treatment options outside the region or
country,” “lack of information about pain management and
referral to pain professionals,” and “lack of advice regarding
dietary restrictions or playing sports.” A list of the missing
items, general remarks, and quotes is provided in Supple-
mental Tables 3 and 4.
3.3. British versus Dutch Patients. Overall, British patients
gave higher scores for each issue compared to Dutch patients
(M-score 2.2 (UK) vs. M-score 1.5 (NL)) (Supplemental
Table 2). Differences in score of more than 1 point between
Dutch and British patients are displayed in Supplemental
Figure 1. Additionally, priority scores of Dutch and British
HCPs and scores of participating patients and HCPs from
the Netherlands and the UK were compared (Supplemental
Table 2).'e total cohort of patients was too small to identify
any differences between subgroups (e.g., initial treatment
type, tumour location, and age at diagnosis).
3.4. Healthcare Providers. In the Netherlands, HCPs were
invited to six sarcoma centres. All HCPs from the UK were
employees at the Royal Marsden Hospital, London. Twenty-
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one Dutch and ten British HCPs responded. Professional
backgrounds included surgical oncologist (n� 12), medical
oncologist (n� 6), radiation oncologist (n� 5), specialized
sarcoma nurse (n� 5), and other professions including a
radiologist, physiotherapist, and pain specialist (all n� 1).
Seventeen professionals had more than 10 years of experi-
ence, three had 6–10 years of experience, and eleven had 5 or
less years of experience working with desmoid patients.
Frequency of contact with DTF patients varied between once
a week (n� 9, 29%) to rarely (less than once every 3 months)
(n� 1, 3%).
Issues with the highest scores according to HCPs included
“worries about tumour growth” (M-score 3.4), “stress about
the diagnosis” (M-score 3.2), “the experience of uncertainty
during the course of the disease” (M-score 3.2), “pain” (M-
score 3.2), “concerns about the future” (M-score 3.0), “stress
around check-ups during the follow-up” (M-score 3.0), “fear
of recurrence after treatment” (M-score 3.0), “fear of tumour
growth/tumour growth into adjacent tissues or organs” (M-
score 2.9), and “the feeling that patients do not have a clear
prognosis” (M-score 2.9). Overall, HCPs from the UK gave
higher scores, compared to Dutch HCPs withM-scores of 2.8
and 2.0, respectively (Supplemental Table 2).
3.5. Participating Patients versus Healthcare Providers.
'ere was considerable overlap between the highest ranked
issues according to patients and HCPs, particularly re-
garding the unpredictable growth pattern of DTF tumours
(Supplemental Table 1). HCPs scored significantly higher
(p< 0.05) on 77 out of a total of 77 of 124 issues. HCPs also
gave a higher mean overall score on the issues list (total M-
score 2.3) compared to patients (total M-score 1.8) (Sup-
plemental Table 2).
3.6. EORTC QLQ-C30: Dutch vs. British Participating
Patients. Overall, the mean summary score for the EORTC
QLQ-C30 for all DTF patients together was 78.1, with a mean
global health score of 68.7 (Table 3). Statistically significant



















































Figure 1: Flow diagram of participating patients and healthcare providers’ responses to this survey.
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found for “global health,” “insomnia,” for the symptom scales
“pain” and “fatigue,” and for the following functioning scales
“cognitive functioning,” “emotional functioning,” “social
functioning,” and “role functioning” (Table 3).
3.7. EORTC QLQ-C30: Participating Patients versus the
Matched General Population. After 1 :10 nearest-neighbour
matching based on nationality, sex, and age, data of 170
people from the Dutch general population and data of 80
people from the British general population were selected to
compare scores between DTF patients and the general
population. Four British patients were excluded from this
analysis due to missing data regarding their age at the time of
questionnaire completion. Dutch patients had a score of 77
for global health and a summary score of 87.2, whereas scores
for the matched Dutch population were 78.7 and 89.8 for
global health and the summary score, respectively. British
patients (n� 8) had a score of 59.4 for global health and a
summary score of 68.2, whereas scores for thematched British
population were 60.2 and 76.7 for global health and the
summary score, respectively (Table 3) [16]. Dutch partici-
pating patients scored lower on all functioning scales com-
pared to the general Dutch population, although only the
physical functioning score (p � 0.019) and the role func-
tioning score (p � 0.021) showed a statistically significant
difference (Table 3). No statistically significant differences
were found comparing EORTC QLQ-C30 scores between the
British patients and the British general population.
4. Discussion
'e purpose of this study was to identify the most important
HRQoL issues for patients with sporadic DTF and rank them









Sex Male 10 (35%) 5 (29%) 5 (42%)
Female 19 (65%) 12 (71%) 7 (59%)
Median age in years at the time of questionnaires (IQR)b 43 (36–55) 44 (36–55) 41 (32–56)
Median age in years at the time of diagnosis (IQR)c 38 (30–48) 38 (30–48) 37 (28–50)
Tumour localisation Abdominal wall 2 (7%) 2 (12%) 0 (0%)
Intra-abdominal 10 (35%) 8 (47%) 2 (17%)
Extremity/girdles/chest wall 15 (52%) 6 (35%) 9 (75%)
Head/neck/intrathoracic 1 (3%) 1 (6%) 0 (0%)
Missing value 1 (3%) 0 (0%) 1 (6%)
Recurrent disease Yes 6 (21%) 2 (12%) 4 (33%)
No 21 (72%) 15 (88% 6 (50%)
Missing value 2 (7%) 0 (0%) 2 (17%)
Received treatments (some patients gave multiple
answers) Wait and see 21 12 9
Surgery 14 8 6
Radiotherapy 4 1 3
Chemotherapy 5 1 4
Nonsteroidal anti-inflammatory
drugs 8 1 7
Hormonal treatment 7 2 5
Pain management 9 0 9
Physiotherapy 7 3 4
Occupational therapy 2 1 1
Currently receiving any active form of treatment Yes 9 (31%) 0 (0%) 9 (75%)
No 19 (66%) 17 (100%) 2 (17%)
Missing value 1 (3%) 0 (0%) 1 (8%)
Comorbidity (some patients gave multiple answers) No 11 6 5
Arthritis or long-term joint problem 3 2 1
Asthma or long-term chest problem 4 2 2
Diabetes 1 1 0
High blood pressure 1 0 1
Kidney or liver disease 1 1 0
Long-term back problem 6 3 3
Long-term mental health problem 2 2 0
Long-term neurological problem 1 1 0
Physical disability 2 1 1
Othersd 3 2 1
Missing value 2 2 0
aPercentages may not add up to 100% due to rounding up of decimals. bAnswered by n� 21 participating patients. cAnswered by n� 29 participating patients.
dIncluding digestive problems, coeliac disease lactose intolerance, and iron deficiency.
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according to relevance. 'e most highly ranked HRQoL
issues by patients with DTFwere related to the unpredictable
disease trajectory of DTF. Additionally, issues regarding the
rarity, aggressiveness, and the benign classification of DTF
received high scores. From the patient perspective, this
benign classification was seen as misleading, as DTF can
display aggressive growth. In terms of the healthcare system,
the benign disease classification, not being cancer, can have
both pros and cons as it can have consequences for insur-
ances and covering of expenses, depending on the country of
residence. As the aforementioned items are not included in
the EORTC QLQ-C30 questionnaire, a tailored DTF
HRQoL tool could capture these issues. Physical symptoms
such as pain, fatigue, and loss of muscle strength also re-
ceived high priority scores of 2.4, 2.3, and 2.3, respectively.
Although these items are covered by the EORTC QLQ-C30
questionnaire, the results of this study highlight the im-
portance of physical symptoms, caused by the tumour or as a
side effect of treatment, and their impact on HRQoL. Pa-
tients identified several important issues that were not
covered by other questionnaires. 'ese could be considered
in the development of a future DTF-specific HRQoL tool.
In a rare and heterogeneous disease, such as DTF,
measuring the impact of the disease on patients can be
challenging. 'is can be due to the variable disease pre-
sentation, course, and response to treatment and due to the
Table 2: Top 10 most important issues according to the number of participating patients (n).
n Prevalence ratio (%)
Participating patients (total n� 16)a
Worries about tumour growth 10 62.5
Fear of the tumour growth and/or tumour growing into adjacent tissues or organs 9 56.3
Feeling that there is something in your body that does not belong there 7 43.8
Stress around check-ups during the follow-up 6 37.5
Pain 6 37.5
Reaching a definite diagnosis is time consuming 5 31.3
Not being able to sleep because of pain
Feeling frustrated about the “benign” diagnosis with malignant features 5 31.35 31.3
Desmoid-type fibromatosis is unknown among most doctors 5 31.3
Healthcare providers (total n� 31)
Worries about tumour growth 17 54.9
Experience of uncertainty during the course of disease 12 38.7
Pain 11 35.5
Lack of optimal treatment options and/or uncertainty about preferred treatment 10 32.3
Concerns about the future
10 32.3
a n� 13 participating patients failed to provide a top 10.'e cutoff value for inclusion in the DTF-specific HRQoL questionnaire is a prevalence ratio of >30%.




















Dyspnoea 10.3 (23.7) 8.0 (15.1) 11.8 (28.7) 0.845 8.2 (19.1) 18.7 (11.8)
Insomnia 31 (38.8) 55.6 (38.4) 13.7 (29.0) 0.004∗ 20.8 (25.1) 37.9 (39.6)
Appetite loss 14.9 (26.1) 22.2 (21.7) 9.8 (28.3) 0.073 2.9 (11.9) 16.2 (24.8)
Constipationa 16.7 (32.1) 21.2 (37.3) 13.7 (29.0) 0.781 4.7 (13.7) 14.6 (30.9)
Diarrhoea 17.2 (30.4) 27.8 (39.8) 9.8 (19.6) 0.325 7.3 (17.9) 14.2 (45.2)
Financial difficulties 11.5 (24.0) 22.2 (29.6) 3.9 (16.2) 0.059 5.7 (18.9) 23.3 (34.5)
Nausea/vomiting 7.5 (17.6) 13.9 (24.4) 2.9 (8.8) 0.180 4.7 (13.7) 14.6 (28.8)
Pain 33.9 (36.0) 58.3 (37.3) 16.7 (23.6) 0.004∗ 16.2 (21.9) 29.4 (40.3)
Fatigue 31 (32.9) 49.1 (29.0) 18.3 (29.9) 0.004∗ 22.5 (22.4) 33.9 (32.2)
Cognitive functioning 79.9 (30.3) 65.3 (32.1) 90.2 (25.0) 0.030∗ 91.7 (15.7) 76.7 (29.5)
Emotional functioning 73.6 (32.4) 59.0 (33.6) 83.8 (28.2) 0.021∗ 84.3 (18.9) 67.3 (36.7)
Social functioning 77.6 (29.6) 58.3 (33) 91.2 (17.8) 0.001∗ 94.2 (14.9) 75.4 (38.8)
Physical functioning 75.2 (27.9) 67.8 (32.5) 80.3 (23.9) 0.394 92.5 (13.1) 80.2 (33.3)
Role functioning 71.8 (32.8) 52.8 (40.1) 85.3 (17.6) 0.027∗ 91.8 (19.5) 76.5 (38.8)
Global health status 68.7 (27.7) 56.9 (29.5) 77.0 (23.9) 0.043∗ 78.7 (18.2) 60.2 (34.6)
Summary score 78.1 63.5 87.2 89.8 76.7
aData missing from 1 British patient; ∗statistically significant difference. Mean scores with standard deviation (SD) are displayed for all scales of the EORTC
QLQ-C30.'e p value represents the comparison of the scores of the British participating patients versus the scores of the Dutch participating patients. Two-
sided p< 0.05 was considered statistically significant.
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knowledge gap of the natural history of the disease [20].
Moreover, the limited number of responses challenges re-
search in this field. Our cohort may not be representative of
the entire DTF population as the majority of patients in this
cohort had an intra-abdominal tumour and many patients
received one or multiple “active” forms of treatment.
In addition to physical, emotional, and psychological
problems, patients with DTF might also experience social
isolation due to lack of peers with the same condition [20].
'is was reflected in the current study by a relatively high
score for the issue “not knowing peers with the same dis-
ease.” Furthermore, lack of information was identified as a
relevant topic as the following issues: “DTF is unknown
among most doctors” and “lack of information received
about DTF” received M-scores of 2.6 and 1.8, respectively.
HCPs may treat a limited number of patients with this
rare disease; therefore, patients may receive an incorrect
diagnosis or delay in diagnosis due to lack of experience in
recognizing and treating the disease [20]. 'e comparison in
relevance scores between patients and HCPs shows that
HCPs scored significantly higher on a large number of is-
sues, suggesting that they recognize and acknowledge
problems faced by this patient group. 'e issue “reaching a
definite diagnosis is time consuming” received anM-score of
2.3, showing that this is a relevant problem for this patient
group. Whilst the future DTF-specific HRQoL tool will be
available upon diagnosis, it is important for HCPs to con-
sider that patients may have encountered difficulties
reaching the correct diagnosis and so provision of clear
information and support at this time is essential. Accessing
specialists with knowledge of DTF can be challenging, as
they may be located in regional specialist centres. 'is can
result in patients receiving multiple treatment recommen-
dations before seeing a specialist.
Financial consequences, due to insurance problems, the
need to take time off work or increasing traveling costs can
also affect HRQoL, although the issues regarding these
subjects all received relatively low scores in the current study
[21]. Social problems, such as the burden of having a rare
disease on family and carers, as well as having this diagnosis
at a young age, can also have a negative impact on HRQoL
[20, 21].
'is unique study identified important issues for DTF
patients and compared the views of British and Dutch pa-
tients. Most issues were scored higher by British patients
compared to Dutch patients (indicating a higher relevance
for the specific issue). 'is phenomenon was also seen
comparing EORTC QLQ-C30 scores, as British patients
scored statistically significantly lower (indicating worse
functioning) on four out of five function scales, and for the
symptom scales insomnia, pain, and fatigue. Although both
participating centres are tertiary centres visited by patients
with more complex or advanced disease, the catchment area
of the Royal Marsden Hospital (London, UK) is larger than
that of the Erasmus MC (Rotterdam, NL) possibly creating
selection bias during this study. Norm data obtained by the
EORTC of the general Dutch and British population showed
a comparable trend with higher scores on symptom scales
and single items scales (indicating greater symptom burden)
and lower scores on functioning scales (indicating worse
functioning) comparing the data from the general Dutch and
British population. Data from 2017 of 'e Organisation for
Economic Co-operation and Development show similar
results with lower scores (indicating a lower well-being) of
British participants compared to Dutch participants on
several measures of well-being (e.g., housing, income, ed-
ucation, and health and life satisfaction) [22]. 'is suggests
that although our data might show differences between both
countries of “impact of disease” on HRQoL, baseline scores
in the normal population differ and that the experience of
HRQoL issues depends on where you live [16, 22].
Comparisons between patients and a matched cohort of
the general population based on nationality, sex, and age did
not yield significant results, except for “physical function-
ing” and “role functioning” comparing the Dutch patients
with the Dutch general population. Additionally, we com-
pared the scores of HCPs and participating patients. An
important finding of this study was the clear overlap of issues
that were important to patients and HCPs. 'e HCPs rated
various issues higher than patients particularly with regard
to pain, stress about the diagnosis, and concerns about the
future.
We acknowledge that this study has several limitations.
'e small sample size is explained by the rarity of DTF. A
larger cohort is needed to test the psychometric aspects of a
DTF-specific HRQoL tool in future studies. 'e response
rate was lower than we had hoped for, but similar response
rates have been published in studies describing more
common diseases such as cancer [23]. In the current study,
the relatively low response rate may have been due to the
length of the questionnaire, the single-centre setup (one
centre in each country), the timing of sending out the
questionnaire (midsummer), and/or the overall reluctance
to participate in a survey study. Furthermore, many patients
also need to complete questionnaires as part of their regular
healthcare; therefore, patients might be less willing to
complete questionnaires for research purposes. Sending out
a reminder to patients would have been a valid option to
increase the response rate. Selection bias may have led to an
overestimation of HRQoL problems in our cohort. As the
primary aim was to identify the most relevant issues in this
patient group, the effect of this overestimation is less rele-
vant. A population-based cohort is required to determine the
true prevalence of issues and perhaps a more representative
result. Lastly, interpretation of the questions is influenced by
the current health situation of each patient. We tried to
eliminate such influencing factors by excluding patients with
a diagnosis of cancer and FAP-associated DTF. However,
patients HRQoL might also be influenced by disease stage,
tumour location, and treatments and by other comorbidities
and personal circumstances. 'is impact on HRQoL issues
could be evaluated in a future population-based cohort study
and stresses the need for validation of our findings in a large,
international DTF cohort to evaluate the prevalence of
HRQoL issues.
Today, solely one DTF-specific questionnaire, the
Gounder/DTRF Desmoid Symptom/Impact Scale, is avail-
able and currently mainly used in the setting of clinical trials
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[24–26]. 'e findings of our study will be used for the
development of a DTF-specific tool, according to the
EORTC guidelines, which can be used, accompanied by the
EORTC QLQ-C30 HRQoL instrument and will be useful for
observational studies, clinical trials, and clinical care.
Implementation of this tool and action on abnormal find-
ings, concerns, or poor experiences of patients might im-
prove satisfaction with healthcare, symptom management,
and HRQoL [27]. Healthcare providers may benefit from
being able to anticipate and identify problems earlier,
thereby improving work efficiency and promoting patient-
centred care through shared decision-making [28–30]. In
order for a tailored HRQoL tool to work in clinical practice,
this tool should add value to the clinical workflow without
disrupting it [31]. Our results will be used in the develop-
ment of an international, multicentre, population-based
study in line with the EORTC guidelines for developing a
questionnaire [14]. 'is study includes pretesting and
content validation of a DTF-specific questionnaire. 'is
questionnaire will assess the prevalence of HRQoL issues
and will identify risk factors for the development of HRQoL
issues patients experience. Patients will receive an invitation
to participate in an online survey and one reminder for
completing the questionnaire. When this tool has been
developed and validated, it will reflect overall patient ex-
perience and its multidimensional contributing factors by
including important nonsymptom, disease-specific areas
regarding the unpredictable course of this rare disease. 'e
tool could be used alongside the EORTC QLQ-C30, to gain
more insight into HRQoL issues of the patient at diagnosis.
Additionally, longitudinal studies could evaluate HRQoL
issues of DTF patients during their disease trajectory, and
the questionnaire can potentially be used in both clinical and
research settings.
5. Conclusions
'is study identified relevant issues for DTF patients to be
considered in the future development of a DTF-specific
HRQoL questionnaire. Issues regarding the unpredictable
growth behaviour and rarity of DTF were the most highly
ranked by patients and HCPs. Additionally, this study
identified differences in priority scores between British and
Dutch patients. Although this could be due to selection bias,
field testing in a large, international cohort is needed to
confirm any potential cultural findings.
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